AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03874949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEALITE Regular
Description: Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
Study NCT03874949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEALITE Ultra
Description: Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
Study NCT04169802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal Health Monitoring System Visual Acuity Module
Description: Assessment of corrected near visual acuity
Study NCT02515955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
Study NCT04169802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Description: Assessment of corrected near visual acuity
Study NCT01601210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate
Study NCT01601210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate or placebo
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate
Study NCT05987436 — intervention group
Intervention type: OTHER
Intervention: Supervised Aerobic Exercise
Description: Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
Study NCT00975663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Description: Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
Study NCT00975663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and MMF
Description: Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
Study NCT01381536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1550188 1mg/kg or 10mg/kg
Description: IV one shot
Study NCT02264548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio-Ablation
Description: Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
Study NCT02076906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance High Intensity Focused Ultrasound
Description: MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
Study NCT01067365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 12.5 mg once daily
Study NCT01067365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 25 mg once daily
Study NCT03346967 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adipose-derived mesenchymal stem cells
Description: Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
Study NCT00909740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous escalating dose
Study NCT03342092 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
Study NCT00779207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss and exercise
Description: 10% weight loss through diet and exercise plus multicomponent exercise training three times a week
Study NCT00779207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss
Description: 10 percent weight loss through diet and behavioral modification
Study NCT01781780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Nutrition Recommendations
Study NCT01781780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Recommendation
Study NCT01781780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Breakfast Recommendation
Study NCT00953563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unite Biomatrix
Description: collagen based, decellularized equine pericardial dressing for skin surface wounds
Study NCT00548899 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nexavar (Sorafenib)
Description: Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
Study NCT01124955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
Study NCT01124955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-penetrating acupuncture
Description: The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
Study NCT02744417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
Study NCT02744417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
Study NCT02744417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
Study NCT02744417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: bupropion hydrochloride 150mg
Study NCT02744417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0,5mg
Study NCT01441466 — intervention group
Intervention type: OTHER
Intervention: Isolation
Description: Patients in this arm are nursed together (in the same room) independent of viral agent
Study NCT01569230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
Study NCT01569230 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
Study NCT01569230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
Study NCT01569230 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting
Description: No interventions were applied to the patients in this group.
Study NCT03582696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHANGE Study
Description: The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
Study NCT03778463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synovectomy
Description: Removal of the synovium during total knee arthroplasty
Study NCT04671992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Out of-Plane Technique and In-Plane on
Description: A comparison of out of-plane technique and in-plane
Study NCT05323097 — intervention group
Intervention type: OTHER
Intervention: Drowning-related OHCA
Description: Drowning-related out-of-hospital cardiac arrest (OHCA): YES
Study NCT01515046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with escalating ascorbic acid
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)
Study NCT03100110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCognitive Communicator
Description: Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
Study NCT01220180 — intervention group
Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
Study NCT01220180 — intervention group
Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered.
Study NCT01220180 — intervention group
Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
Study NCT03462381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
Study NCT03462381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
Study NCT00857519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Carboplatin
Description: Intra-arterial chemotherapy.
Study NCT02385435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal Bupivacaine 2 mg/kg single shot
Study NCT02385435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1μg.kg-1
Description: Caudal dexmedetomidine 1μg.kg-1, single shot
Study NCT02385435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2μg.kg-1
Description: Caudal dexmedetomidine 2μg.kg-1, single shot
Study NCT00542061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: half-yearly monitoring routine
Description: A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
Study NCT02086422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Study NCT02086422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02086422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Study NCT02086422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT00629798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Description: Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
Study NCT01801852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Study NCT03135977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, Etoposide
Description: Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
Study NCT03281304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,500 5 mg
Description: CP-690,550 5 mg tablet BID
Study NCT03281304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 10 mg
Description: CP-690,550 10 mg tablet BID
Study NCT00801021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse
Description: Rinse with 15ml twice daily then expectorate
Study NCT02684188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced rural discharge and transition
Description: While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
Study NCT02161419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roniciclib (BAY1000394)
Description: Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
Study NCT02161419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Study NCT04196673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon SN60WF
Description: Implantation of an intraocular lens Alcon SN60WF
Study NCT04196673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hoya Vivinex
Description: Implantation of an intraocular lens Hoya Vivinex
Study NCT03693781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 1 MG Oral Tablet
Description: Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or \<71 kg) for 30 weeks of duration.
Study NCT03693781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Corresponding tablets for 30 weeks
Study NCT03389178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cohen Perceived Stress Scale-10 (PSS-10)
Description: Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 5 mg/mL, 4 mL intrathecally as a single dos
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.4 mg/mL; 0.5 mL intrathecally as a single dosage
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
Study NCT01493921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle gel
Description: Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study NCT01005602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digoxin Dosing per Nomogram
Description: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
Study NCT01005602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
Study NCT01005602 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin
Description: All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
Study NCT03040453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microwave ablation
Study NCT03040453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Irreversible electroporation
Study NCT00667953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Gleevec (600 mg) daily.
Study NCT00667953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
Study NCT03523455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Aid IPS (Iron Protein Succinylate)
Description: Taken orally in capsule form
Study NCT03523455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form
Study NCT02404480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
Study NCT05467631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical oil application
Description: Topical Comparison
Study NCT05467631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical oil application
Description: Topical Comparison
Study NCT01320501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All patients will receive: TarcevaTM 150mg/day PO.
Study NCT02861014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
Study NCT02174978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP012 with AS01B adjuvant system
Description: Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
Study NCT02174978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P falciparum Controlled Human Malaria Infection (CHMI)
Study NCT02174978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: P falciparum Controlled Human Malaria Infection (CHMI)
Study NCT00831194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized diet plan and PDA self reporting.
Description: Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.